Get the Stockscreener App
5.94
2.24%
0.13
Mannkind Corp stock is traded at $5.94, with a volume of 3.39M.
It is up +2.24% in the last 24 hours and up +13.14% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
See More
Previous Close:
$5.81
Open:
$5.83
24h Volume:
3.39M
Relative Volume:
0.86
Market Cap:
$1.82B
Revenue:
$248.37M
Net Income/Loss:
$11.74M
P/E Ratio:
118.80
EPS:
0.05
Net Cash Flow:
$18.24M
1W Performance:
+4.58%
1M Performance:
+13.14%
6M Performance:
+55.09%
1Y Performance:
-9.31%
1-Day Range:
$5.785
$6.01
1-Week Range:
$5.585
$6.01
52-Week Range:
$3.3812
$7.07
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
5.94 | 1.78B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Oct-10-25 | Initiated | Leerink Partners | Outperform |
| Jul-16-25 | Resumed | H.C. Wainwright | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-10-25 | Initiated | Wedbush | Outperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
MannKind stock price target raised to $9 by Leerink on Tyvaso DPI royalties - Investing.com
MannKind (NASDAQ:MNKD) CEO Michael Castagna Sells 107,920 Shares of Stock - MarketBeat
MannKind (MNKD) Valuation Check After FDA Filing Progress for FUROSCIX ReadyFlow Autoinjector - simplywall.st
Mannkind EVP Thomson sells $823k in shares By Investing.com - Investing.com South Africa
Insider Selling: Michael Castagna Sells Shares of MannKind Corp (MNKD) - GuruFocus
Mannkind EVP Thomson sells $823k in shares - Investing.com
Mannkind CEO Castagna sells $601k in shares By Investing.com - Investing.com UK
Mannkind CEO Castagna sells $601k in shares - Investing.com
MannKind Corp Executives Sell Shares - TradingView
VP Thomson Sells 147,780 ($823.1K) Of MannKind Corp [MNKD] - TradingView
Is MannKind Corporation (NNFN) stock undervalued after correctionWeekly Investment Report & Growth Focused Stock Reports - Newser
How MannKind Corporation (NNFN) stock moves in volatile trading sessionsJuly 2025 EndofMonth & Weekly Momentum Stock Picks - Newser
Is There Now an Opportunity in MannKind After This Year’s Share Price Pullback? - Yahoo Finance
MAI Capital Management Reduces Stock Holdings in MannKind Corporation $MNKD - MarketBeat
Can MannKind Corporation (NNFN) stock attract analyst upgradesQuarterly Profit Report & AI Based Buy and Sell Signals - Newser
Can MannKind Corporation (NNFN) stock sustain double digit ROEMarket Movement Recap & Long Hold Capital Preservation Plans - Newser
FDA Reviewing 10-Second Treatment for Edema in Heart Failure - Diagnostic and Interventional Cardiology
MannKind (MNKD) Awaits FDA Decision on Furoscix Autoinjector - GuruFocus
FDA accepts MannKind’s sNDA for ReadyFlow Autoinjector - Investing.com
MannKind (MNKD) Awaits FDA Decision on FUROSCIX ReadyFlow Autoin - GuruFocus
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease - The Manila Times
MannKind Corporation Announces FDA Acceptance of sNDA for FUROSCIX ReadyFlow™ Autoinjector, Targeting Improved Management of Chronic Heart Failure and Kidney Disease - Quiver Quantitative
MannKind (Nasdaq: MNKD) lands FDA sNDA review, PDUFA July 26, 2026 for ReadyFlow - Stock Titan
Geode Capital Management LLC Grows Position in MannKind Corporation $MNKD - MarketBeat
MannKind (MNKD) Is Up 6.4% After Wave of Analyst Upgrades Despite MNKD-101 Discontinuation – Has The Bull Case Changed? - simplywall.st
Truist Securities Initiates Coverage on MNKD with 'Buy' Rating a - GuruFocus
MannKind stock initiated with Buy rating at Truist on Tyvaso DPI potential By Investing.com - Investing.com South Africa
MannKind stock initiated with Buy rating at Truist on Tyvaso DPI potential - Investing.com
MannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Will MannKind Corporation stock outperform value stocksMarket Activity Recap & Accurate Intraday Trading Signals - newser.com
Is MannKind Corporation (NNFN) stock a contrarian opportunityPortfolio Risk Report & Intraday High Probability Alerts - newser.com
Why MannKind Corporation (NNFN) stock attracts wealthy investorsTrend Reversal & Safe Entry Momentum Tips - newser.com
What momentum indicators show for MannKind Corporation stock2025 Earnings Impact & Step-by-Step Trade Execution Guides - newser.com
How MannKind Corporation stock performs after earningsJuly 2025 PreEarnings & Weekly High Momentum Picks - newser.com
How MannKind Corporation (NNFN) stock trades under stagflationMarket Activity Report & Free Technical Confirmation Trade Alerts - newser.com
Is MannKind Corporation (NNFN) stock attractive post correction2025 Fundamental Recap & Verified Short-Term Plans - newser.com
MannKind at Jefferies London Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Nigeria
Is MannKind Corporation stock cheap compared to fundamentalsShare Buyback & Safe Swing Trade Setups - newser.com
MannKind at Jefferies London Healthcare Conference: Strategic Growth Insights - Investing.com India
Is MannKind Corporation (NNFN) stock a safe buy pre earnings2025 Top Decliners & AI Driven Stock Reports - newser.com
Technical signs of recovery in MannKind CorporationTrade Ideas & Stepwise Trade Signal Implementation - newser.com
Mitsubishi UFJ Asset Management Co. Ltd. Buys Shares of 67,889 MannKind Corporation $MNKD - MarketBeat
SBI Securities Co. Ltd. Acquires 65,184 Shares of MannKind Corporation $MNKD - MarketBeat
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mannkind Corp Stock (MNKD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Castagna Michael | Chief Executive Officer |
Dec 02 '25 |
Option Exercise |
4.55 |
107,920 |
491,036 |
2,612,712 |
| Castagna Michael | Chief Executive Officer |
Dec 02 '25 |
Sale |
5.57 |
107,920 |
601,114 |
2,504,792 |
| Thomson David | EVP Genl Counsel & Secretary |
Dec 02 '25 |
Option Exercise |
4.58 |
147,780 |
676,788 |
989,499 |
| Thomson David | EVP Genl Counsel & Secretary |
Dec 02 '25 |
Sale |
5.57 |
147,780 |
823,135 |
841,719 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):